



## KDIGO Direct

### KDIGO Hosts Virtual Home Dialysis Controversies Conference

KDIGO held a Controversies Conference on Home Dialysis from May 9-10, 2021. Co-chaired by Jeff Perl, MD (Canada), and Martin Wilkie, MD (UK), the virtual conference was the third meeting in the KDIGO dialysis conference series. It was also the second time KDIGO held a Controversies Conference

virtually. Though participants missed the camaraderie and in-person engagement that typifies a KDIGO Controversies Conference, the remote setup did not inhibit thought-provoking discussion.



“Perhaps fitting, this virtual conference allowed participants to contribute from the comfort of their own homes,” said Dr. Perl. “The platform successfully brought together a group of diverse stakeholders to generate stimulating discussion, highlight key controversies, and share important insights. The information generated, and report that ensues will serve as an invaluable resource to the global kidney care community in addressing barriers, overcoming challenges, and maximizing opportunities to increase home dialysis utilization while improving outcomes.”

Attendees engaged in a critical, in-depth review of factors that both positively or negatively impact home dialysis use, while considering criteria for candidacy, eligibility, and outcomes associated with home dialysis. Strategies to expand the use of home dialysis, with consideration toward currently escalating ESKD-associated costs, were of particular emphasis, including specific and local factors that impact home dialysis uptake.

“It was my absolute privilege to co-chair the KDIGO Home Dialysis controversies conference with Jeff Perl,” said Dr. Wilkie. “The virtual platform over several linked events brought together experts, including patient partners, from across the world, to energetically contribute their

expertise in a comprehensive examination of Home Dialysis. The resulting publication will be an essential resource for the kidney community."

For more information and related resources, [visit the KDIGO Home Dialysis Controversies Conference website.](#)

## KDIGO Optimal Anemia Management in Chronic Kidney Disease (CKD) Conference Report Now Available



The updated and final version of the [KDIGO Optimal Anemia Management in Chronic Kidney Disease \(CKD\) Conference Report](#) is now available. The report is based on the December 2019 KDIGO Optimal Anemia Management in CKD Controversies Conference held in Barcelona, Spain. Dr. Tilman B. Drüeke (France) and Dr. Jodie L. Babitt (USA) co-chaired this conference.

The conference focused largely on iron, including the contribution of iron pathophysiology to the anemia of CKD and adverse patient outcomes, iron therapeutic agents, and the impact of other current and emerging anemia therapies on hemoglobin targets, iron parameters, and iron supplementation needs.

The goal of this KDIGO conference was to determine best practice and areas of uncertainties in the treatment of anemia, review key relevant literature published since the 2012 KDIGO Anemia Guideline, identify new topics or issues to be revisited for the next iteration of the KDIGO guideline, and outline research needed to improve anemia management in CKD. [Read the Conference Report.](#)

**Register for "Optimal Anemia Management in CKD: A New Paradigm in Treatment?"**



Drawing upon the discussions and conclusions from the KDIGO Optimal Anemia Management Controversies Conference, this webinar will explore new therapies and treatment options relevant to the management of anemia in CKD.

"Optimal Anemia Management in CKD: A New Paradigm in Treatment?" will take place on Wednesday, June 16, at 09:00 hrs EDT (15:00 hrs CEST). [Learn more and register for the webinar.](#)

Moderated by Dr. Tilman Drüeke (France), the webinar features presentations by Dr. Jodie Babitt (USA) and Dr. Francesco Locatelli (Italy).

## Share Your Feedback on the KDIGO Novel Anemia Therapies in CKD Controversies Conference Scope of Work



KDIGO Controversies Conference on  
Novel Anemia Therapies in CKD  
-Scope of Work-

Kidney Disease Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve the care and outcomes of kidney disease patients worldwide by promoting coordination, collaboration, and integration of initiatives to develop and implement clinical practice guidelines. Periodically, KDIGO hosts conferences on topics of importance to patients with kidney disease. These conferences are designed to review the state of the art on a focused subject and determine what needs to be done in this area to improve patient care and outcomes. Sometimes the recommendations from these conferences lead to KDIGO guideline updates, efforts, and other times they highlight areas for which additional research is needed.

### BACKGROUND

In patients with kidney disease, anemia is a multifactorial disorder resulting from a combination of low erythropoietin production, abnormal iron metabolism (e.g., absolute/functional iron deficiency, impaired absorption of dietary iron through the gut), blood loss, inflammation, nutritional deficiencies, and oxidative stress. Current treatment of anemia includes oral or intravenous iron and the use of erythropoiesis stimulating agents (ESA).

Clinical trial data have indicated that ESA, when used to target the low-normal hemoglobin range, do not improve survival and actually confer serious cardiovascular outcomes such as stroke<sup>1</sup> and cardiovascular events<sup>2,3</sup> in chronic kidney disease (CKD) patients, including those treated with dialysis. As a result, current KDIGO guidelines suggest that ESA may be considered when Hb is below 10 and ESA should not be used to maintain the concentration above 10.5. There have also been concerns about the safety of intravenous iron, specifically in relation to reported increased risk of infections but the recent PROVAL trial demonstrated that proactive iron replacement

KDIGO cordially invites you to provide feedback on the Scope of Work for the Novel Anemia Therapies in Chronic Kidney Disease (CKD) Controversies Conference. The Scope of Work and feedback form can be found on the [KDIGO Novel Anemia Therapies in CKD Controversies Conference website](#). Kindly submit your comments via the feedback form no later than Friday, July 9.

This conference, scheduled for December 2021, will be the second in the KDIGO Anemia Controversies Conference series. The goals for this conference are

to determine best practices and areas of uncertainty in the treatment of anemia, review key relevant literature published since the 2012 KDIGO Anemia Guideline, address ongoing controversial issues, identify new topics or issues to be revisited in the next iteration of the KDIGO guideline, and outline research needed to improve anemia management in CKD. One key question this conference will address is whether there is a specific population in which HIF-PHI should be preferred or avoided. Dr. Elaine Ku (USA) and Dr. David C. Wheeler (UK) will co-chair this conference.

[Read the Scope of Work and submit comments via the feedback form.](#)

## KDIGO CKD-MBD Guideline Webinar Addresses New Evidence for Potential Guideline Update

The poster features the KDIGO logo at the top left. The main title is "KDIGO CKD-MBD GUIDELINE: 4 Years On and Time for Change?". Below the title, it lists the moderator, RUKSHANA SHROFF, and three panelists: MARKUS KETTLER (PTH Management and Vitamin D: Breakthroughs or Steady State?), MARC VERVOLET (Control of Phosphate and Calcium in CKD: What are the Implications of Novel Studies for the KDIGO Guideline?), and RUKSHANA SHROFF (Moderator). There are also portraits of Markus Kettler and Marc Vervloet. A QR code is present with the text "CLICK OR SCAN TO WATCH". At the bottom, it says "This webinar was supported by an unrestricted educational grant from Vifor Pharma."

It has been a few years since KDIGO last updated its Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Clinical Practice Guideline. Is it time for another update? Attendees debated and discussed this question in an April 29 webinar. The webinar recording is now available for viewing at any time

on the [KDIGO YouTube channel](#).

Chaired by Dr. Rukshana Shroff (United Kingdom), the webinar explored the ways in which the landscape has changed since the publication of the 2017 KDIGO CKD-MBD Guideline. Topics of discussion included emerging evidence and new data in the area of CKD-MBD and its impact on PTH management and vitamin D. It also covered implications for the control of phosphate and calcium in CKD, and includes an interactive panel discussion with live Q&A.

[Watch the KDIGO CKD-MBD Guideline Webinar.](#)

## Coming Soon: The KDIGO Conversations in Nephrology Podcast



Coming soon from KDIGO: The Conversations in Nephrology Podcast. Stay tuned for more information on this exciting new series covering key topics in nephrology with the world's leading experts.

Follow us on social media for more information on the podcast release date, upcoming topics, new speakers, and more.

## Attending ERA-EDTA 2021 Virtual Congress?



Are you attending the 58th ERA-EDTA Congress? If so, make sure to attend the KDIGO sessions, which will feature a series of speakers discussing the KDIGO Diabetes Management in CKD and Blood Pressure Management in CKD Guidelines.

The KDIGO Diabetes Management in CKD Guideline presentations will take place on **Sunday, June 6, 8:00 - 9:30 AM** (CEST). These include:

- **KDIGO Guideline for Diabetes in CKD (HBA1c and Beyond)** with KDIGO Diabetes Guideline Co-Chair, Dr. Peter Rossing (UK)
- **Organ Protection: The New Concept** with Dr. Megumi Oshima (Japan)
- **Standard-of-Care and Self Management** with KDIGO Co-Chair, Dr. Michel Jadoul (Belgium)

The KDIGO Blood Pressure Management in CKD Guideline presentations will take place on **Monday, June 7, from 15:00 - 16:30 PM** (CEST). These include:

- **KDIGO 2021 Blood Pressure in CKD Guideline: A Controversial Guideline?** with KDIGO Blood Pressure Guideline Co-Chair, Dr. Johannes Mann (Germany) and Dr. Carmine Zoccali (Italy)
- **Lowering Systolic Blood Pressure in CKD to <120 mm Hg is Reasonable**, with KDIGO Blood Pressure Guideline Co-Chair, Dr. Alfred Cheung (USA), and Dr. Indranil Dasgupta (UK)
- **Blood Pressure Measurement in the Office: Standardized Measurement is Vital and Feasible** with Dr. Bernard Kraemer (Germany) and Dr. Rajiv Agarwal (USA)

Don't miss the chance to take part in these engaging presentations. [Register for the 58th ERA-EDTA Congress.](#)

## Reminder! Check out the ISN-KDIGO CKD Early Identification & Intervention Toolkit



Chronic kidney disease (CKD) causes substantial global morbidity and increases cardiovascular and all-cause mortality, so identifying and treating it at the earliest stages is a worldwide imperative.

To this end, the International Society of Nephrology (ISN) and KDIGO have released a series of tools for CKD early identification and intervention aimed at kidney health professionals, primary care physicians, and nurses working in primary care settings. Discover and access these tools on the [ISN-KDIGO CKD Early Identification and Intervention Toolkit website](#), including an [introductory video](#).

## KDIGO in the News



### **Science Direct: KDIGO Optimal Anemia Management Conference Report**

In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluation, and treatment of anemia in chronic kidney disease. [Read more.](#)



### **Nephrology News & Issues: Dialysis Providers Can Disrupt the CKD-MBD Treatment Paradigm**

For several decades, the kidney care community has had a “vitamin D first” therapeutic approach to reducing parathyroid hormone (PTH), one of the key laboratory abnormalities related to chronic kidney disease-mineral bone disorder (CKD-MBD). [Read more.](#)

## About KDIGO

KDIGO is a Belgian foundation committed to developing and implementing nephrology guidelines that improve patient outcomes on a global basis. It is an independent, volunteer-led, self-managed charity incorporated in Belgium accountable to the public and the patients it serves.

[Learn More](#)

